Topical Corticosteroid for Pembrolizumab-Induced Rash
For mild-to-moderate rash from pembrolizumab (Keytruda), start with hydrocortisone 1% cream for mild cases (Grade 1) or escalate to moderate-potency topical corticosteroids like clobetasone butyrate 0.05% or prednicarbate 0.02% cream for Grade 2 rash. 1, 2, 3
Grade-Based Treatment Algorithm
Grade 1 Rash (covering <10% body surface area)
- Apply mild-potency topical corticosteroids: Hydrocortisone 1-2.5% cream once daily 1, 2, 3
- For facial involvement, use lower-potency options like hydrocortisone 2.5% or desonide 2
- For body areas, Class I topical corticosteroids (clobetasol propionate, halobetasol propionate, betamethasone dipropionate) can be used 2
- Add emollients applied twice daily (200-400g per week) 4
- Consider oral antihistamines (cetirizine 10mg daily or hydroxyzine 10-25mg at bedtime) for pruritus 1, 2, 3
- Continue pembrolizumab without interruption 2, 3, 5
Grade 2 Rash (covering 10-30% body surface area)
- Escalate to moderate-potency topical corticosteroids: Clobetasone butyrate 0.05% (Eumovate) or prednicarbate 0.02% cream applied once to twice daily 1, 4
- Alternative moderate-potency options include betamethasone valerate 0.025% 4
- Continue emollients and oral antihistamines as above 1, 3
- Continue pembrolizumab but monitor weekly for improvement 3
- If no improvement after 2 weeks, consider short-term oral corticosteroids (prednisone 0.5-1 mg/kg/day) 1, 3
Grade 3 Rash (covering >30% body surface area)
- Use potent topical corticosteroids: Betamethasone valerate 0.1%, mometasone furoate 0.1%, or clobetasol propionate 0.05% 1, 4, 1
- Initiate systemic corticosteroids: Prednisone 0.5-1 mg/kg/day orally, tapered over 2-4 weeks once improved to Grade 1 2, 3
- For severe symptoms, consider IV methylprednisolone 0.5-1 mg/kg/day 3
- Withhold pembrolizumab until rash improves to Grade 1 or mild Grade 2 2, 3, 5
- Obtain dermatology consultation 1, 2, 3
Important Clinical Considerations
Formulation selection matters: Use creams if skin is weeping/moist, and ointments if skin is dry 4. Most preparations are available in both forms 4.
Application amounts: For twice-daily dosing, patients typically need 200-400g per week of topical preparations 4. Face and neck require 15-30g per 2 weeks, while trunk requires approximately 100g per 2 weeks 4.
Avoid common pitfalls: Do not use alcohol-containing gel formulations as they may worsen dryness 1. Topical corticosteroids should be used short-term to avoid skin atrophy 1.
Refractory Cases
If the rash is steroid-refractory after 2-3 weeks of appropriate topical and systemic therapy, consider alternative immunosuppressive agents 6, 7:
- Single-dose methotrexate 15mg has shown efficacy for lichenoid dermatitis 6
- Short course of oral cyclosporine for severe lichenoid eruptions 7
- Topical roflumilast cream 0.3% once daily for persistent pruritus refractory to corticosteroids 8
Critical warning: Immediately discontinue pembrolizumab and obtain urgent dermatology consultation if signs of Stevens-Johnson Syndrome, toxic epidermal necrolysis, or DRESS syndrome develop (skin sloughing >30% BSA, mucosal involvement, systemic symptoms) 3, 5. These require IV methylprednisolone 1-2 mg/kg/day and hospitalization 3.
The pembrolizumab FDA label confirms that immune-mediated dermatologic reactions occur in 1.4% of patients, with most cases (79%) resolving with appropriate management 5. Topical emollients and/or topical corticosteroids are adequate to treat mild-to-moderate non-exfoliative rashes 5.